real-time clinical trials

For nearly six decades, the way data moves through a clinical trial has barely changed. A site collects it, a sponsor analyzes it, and the FDA eventually receives it, months or years after the fact. That lag has delayed regulatory decisions, slowed drug development timelines, and in some cases, kept promising therapies from reaching patients who needed them sooner.

Thankfully, that is starting to change. In late April 2026, the FDA announced something that has been talked about for years but rarely demonstrated, real-time clinical trials. 

The agency unveiled two proof-of-concept studies already underway, one with AstraZeneca and one with Amgen, where safety signals and endpoint data are being shared with the FDA as the trial progresses, not months or years later. Additionally, a broader pilot program is set to launch this summer.

This is a fundamental rethinking of how clinical evidence gets generated and reviewed, with implications for how quickly the industry can move from trial initiation to regulatory decision. The old model was sequential in how it collected data, packaged it, and delivered the data at the end. The new model treats it as something that flows continuously, in real time, to the people who need to act on it.

However, real-time data sharing only works if the data being shared is coherent in the first place. 

‍